MNPR — Monopar Therapeutics Share News
0.000.00%
Last trade - 00:00- $487.17m
- $352.87m
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
U.S. STOCKS ON THE MOVE-Oklo, Fortune Brands, Air Products
Monopar rises after FDA grants rare pediatric disease status to Wilson disease drug
Monopar Therapeutics Q4 net loss narrows on lower R&D costs
Brief: Monopar Expands Leadership Team With Appointment Of Seasoned Biopharma Executive Susan Rodriguez As Chief Commercial And Strategy Officer
U.S. RESEARCH ROUNDUP- Apogee Therapeutics, Intel, Northern Trust
Brief: Monopar Therapeutics Announces Pricing Of $135 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants
Brief: Monopar Announces Abstract Accepted With Distinction For Oral And Poster Presentations At The Upcoming American Neurological Association 2025 Annual Meeting
Brief: Monopar Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million
Monopar Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Monopar Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Monopar Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Monopar Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan’S Employment Terminated